PHILADELPHIA, PA / ACCESS Newswire / July 23, 2025 / The law firm of Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Elanco Animal Health Inc. (NYSE:ELAN) ("Elanco") on behalf of the company’s long-term shareholders.
Click here to receive additional information about your legal rights and options: https://kaskelalaw.com/case/elanco/
Recently an amended securities fraud complaint was filed against Elanco on behalf of certain investors who purchased shares of the company’s stock between May 9, 2023 and June 26, 2024. According to the complaint, during that time period Elanco and several of the company’s senior executive officers made a series of materially false and misleading statements to investors concerning the company’s FDA submission for Zenrelia, without disclosing that a Zenrelia vaccine response study completed on March 13, 2023 had identified significant safety and public health issues that were likely to negatively affect the timing and outcome of the company’s Zenrelia submission to the FDA.
As further detailed in the complaint, on June 27, 2024, the defendants issued a press release disclosing a delay in the commercial launch for Zenrelia, and that Zenrelia’s label was expected to include a black box warning regarding safety, which would inhibit adoption of Zenrelia. The defendants also disclosed that "we expect the U.S. label will include a boxed warning on safety based on the outcome of a trial with unvaccinated dogs dosed at 3x the label dose," and that "we believe this warning will slow the product adoption curve in the U.S. and initially limit the number of expected treatment days by approximately 25%." Following these disclosures, shares of the company’s stock fell $3.70 per share, or over 20% in value, to close on June 27, 2024 at $14.27 per share, on unusually heavy trading volume.
The investigation seeks to determine whether the members of Elanco’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.
Current Elanco shareholders who have owned the company’s shares since at least May 9, 2023 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 for additional information about this investigation and their legal rights and options.
Alternatively, investors may submit their information to the firm by clicking on the following link (or if necessary, by copying and pasting the link into your browser):
https://kaskelalaw.com/case/elanco/
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent, no-cost basis, and has helped to recover hundreds of millions of dollars for aggrieved investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com
This notice may constitute attorney advertising in certain jurisdictions.
SOURCE: Kaskela Law LLC
View the original press release on ACCESS Newswire
COMTEX_467503583/2457/2025-07-23T07:02:03